EU Pharma Strategy: Success depends on access to Generic, Biosimilar and Value Added Medicines

Smart reform of EU pharma and IP legislation key to boosting… 28 June 2022 Generic and biosimilar medicines lower healthcare treatment costs dramatically and…
Access to medicines and security of supply should be central… 13 June 2023 Generic and biosimilar medicines significantly lower healthcare treatment costs and…
Off-patent medicines ready to drive pharma policy reform for… 15 June 2023 The EU has initiated a major overhaul of EU pharma…
Now or never: Europe must seize the Pharma Legislation… 7 November 2023 Medicines for Europe, representing the European value-added medicines industry, is…